The present invention provides a use of carrimycin and a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment and/or prevention of tumors. The carrimycin and the pharmaceutically acceptable salt thereof have good therapeutic effects on a plurality of tumors such as breast adenocarcinoma, liver cancer, lung cancer, kidney cancer, brain tumor, cervical cancer, prostate cancer, spleen cancer, esophagus cancer, gastric adenocarcinoma, colon cancer, lymphoma, or leukemia and, particularly, exhibit significant inhibition of the growth of human breast adenocarcinoma cells MCF-7 and MDA-MB-231, human liver cancer cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cells 786-O, human renal cell adenocarcinoma cells 769-P, and human glioma cells U251.
